Kornimate/medical-research-clean huggingface dataset:
study on periodontal treatment in diabetic patients

Conditions: Diabetes; Gingivitis; Periodontitis

Summary: diabetes is a metabolic disorder that affects the uptake of glucose into cells. this causes a cascade of systemic alterations that may lead to kidney failure, cardiovascular complications, altered tissue healing, retinopathies and gangrene. diabetes is also associated to increased susceptibility to infections and inflammation. it has been observed that diabetic patients suffer more often from oral infections such as periodontal disease. periodontal disease is an infectious-inflammatory disease that leads to destruction of the surrounding tissues of the tooth. it is proposed that the mechanisms responsible for systemic complication are implicated in the development of periodontal disease. this has been evaluated in studies where diabetic patients showed increased levels of inflammatory cytokines, subgingival bacteria and limited response to treatment. its has also been suggested that established periodontitis in the diabetic patient leads to insulin resistance due to infection and liberation of cytokines from periodontal tissues and thus worsening the diabetic condition. this study is aimed to establish the response to periodontal treatment with antibiotics and the kinetics of glucose levels in diabetic patients.


Eligibility criteria:
inclusion criteria: * must be of legal age (≥18 years old). * voluntary participation and signed informed consent. * confirmed type i and ii diabetes. * at least 10 teeth present in mouth. exclusion criteria: * smokers. * pregnant women. * antibiotic consumption 3 months before inclusion. * hiv positive or aids. * allergic reactions to macrolides and specifically to azythromycin. * periodontal treatment 6 months before inclusion.

Keywords: periodontal treatment, diabetes, glycemia, glycated hemoglobin
a comparative effect of echogenic needle for nerve block on acute and chronic postoperative pain

Conditions: Chronic Postoperative Pain

Summary: surgical pain is a common complication after surgery, affecting patient recovery and treatment quality. \>20% of patients suffer from chronic postoperative pain. china has \>70 million surgeries yearly. nerve block manages postoperative pain, with developing nerve block needles now used in clinics. developed needles may have better pain management effects than non-developed ones, but their effect on reducing chronic pain remains unclear. this study aims to explore the effect of developed nerve block needles on postoperative pain and compare them to non-developed needles, providing new ideas and methods for pain management.

surgical pain is one of the common complications after surgery, which seriously affects the recovery and treatment quality of patients. more than 20% of patients will suffer from postoperative chronic pain. according to the data of the national bureau of statistics, there are more than 70 million surgeries in china every year. nerve block is one of the most commonly used methods for postoperative pain management in clinical practice. in recent years, the developing nerve block needle has gradually begun to be used in clinical practice. compared with the ordinary non-developing nerve block needle, it may have a better effect on pain management after surgery, but whether it has a reduction effect on chronic pain after surgery is still unknown. the purpose of this study is to explore the effect of developing nerve block needle on postoperative pain, and to compare the difference between it and the common non-developing nerve block needle, so as to provide new ideas and methods for postoperative pain management.

Eligibility criteria:
inclusion criteria: 1. the age is above 18 years old and below 70 years old. 2. patients whose surgical sites were in the chest, abdomen, upper limbs or lower limbs, including lobectomy, cholecystectomy, gastrointestinal resection, hysterectomy and other elective operations. 3. this operation was the first operation during the hospitalization. 4. consent to participate in this study and sign an informed consent form. exclusion criteria: 1. patients with a history of alcohol or drug addiction. 2. patients with disturbance of consciousness before operation. 3. other conditions considered by the attending physician or researcher to be inappropriate for the study; 4. history of chronic pain. 5. abnormal coagulation function.

Keywords: visualized nerve block needle acute pain chronic pain
ido2 genetic status informs the neoadjuvant efficacy of chloroquine (cq) in brain metastasis radiotherapy

Conditions: Brain Metastasis

Summary: this research is being done to determine if a short course of chloroquine (five weeks) before, during and after whole brain radiation therapy (wbrt) will improve the overall survival of subjects being treated for brain metastases.

hypothesis one: a short course of chloroquine one week prior and four weeks after initiation of wbrt is tolerable and significantly increases the median survival time of patients suffering from brain metastasis as assessed one, three, six, nine, twelve and 24 months post radiotherapy, when compared to historic controls. hypothesis two: the presence of one or both single-nucleotide polymorphisms (snp)s in the gene coding for the immunoregulatory enzyme indoleamine 2,3-dioxygenase 2 (ido2) improves the clinical outcomes of wbrt or the response to cq co-treatment. 3.2. specific aims: the specific aims of this study are: 1. determine patients physical profiles prior wbrt and at regular intervals afterwards up to 24 months after radiotherapy. 2. record the status of patient metastases (i.e. number, location, size) 3. determine patients' kps values. 4. record the incidence and causes of mortality of patients. 5. determine the genotype of ido2 for each patient. 6. following data analysis, test the validity of the two hypotheses.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed primary solid malignancy * patients with single or multiple brain metastases * patients with metastasis diameter \< 5 cm * age \> 18 * clearance from the patient's physician that treatment with chloroquine should not pose a problem to the patient exclusion criteria: * patients with a history of hypotension, cardiomyopathy, epilepsy, seizures * patients with impaired renal function * patients with psoriasis, porphyria * patients with known hypersensitivity to 4-aminoquinoline compounds * pregnancy, nursing * prior radiotherapy * during the chloroquine treatment, patients complaining from visual or auditory disturbances, and patients suffering from acute gastrointestinal problems i.e. anorexia, nausea, vomiting, diarrhea, abdominal cramps

Keywords: chloroquine wbrt survival brain metastasis radiotherapy snps gene coding immunoregulatory enzyme ido2
retrospective study assessing the effect of avapritinib versus best available therapy in patients with advsm

Conditions: Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematological Neoplasm; Mast Cell Leukemia

Summary: blu-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with advsm.


Eligibility criteria:
inclusion criteria for patients in the external control arm: 1. diagnosed with advsm, with known subtype including sm-ahn, asm, or mcl 2. received at least one line of systemic therapy for advsm, which may include but not limited to regimens containing: midostaurin cytoreductive therapy: cladribine, interferon alpha, azacitidine, decitabine selective tkis: imatinib, nilotinib, dasatinib hydroxyurea antibody therapy: brentuximab vedotin 3. adult (≥18 years of age) at the initiation of first systemic line of therapy at the participating site 4. had an index date at least 3 months prior to the start of data collection (in order to include patients with at least 3 months of follow-up after index date), unless date of death occurred less than three months from index date 5. had an approved waiver of informed consent or signed informed consent for participation in the retrospective chart review study, if no institutional waiver from the site was granted exclusion criteria for patients in the external control arm 1. malignancy that is not in remission at time of sm diagnosis, or new non-hematological malignancy diagnosed after sm diagnosis, except for: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site 2. among patients with sm-ahn, presence of either of the following: * patients in whom the sm component is consistent with an indolent systemic mastocytosis (ism) or ssm or, * the ahn component is a lymphoid malignancy, or one of the following myeloid malignancies: acute myeloid leukemia (aml), myelodysplastic syndrome (mds) that is very high-or high-risk as defined by the ipss-r, or a philadelphia chromosome positive malignancy or, * there is a known fip1l1/pdgfra fusion gene (including those with chic-2 deletion and partial deletion of pdgfra), independent of kit mutational status 3. received avapritinib as the first line of systemic therapy for advsm at participating site, or prior to initiation of first systemic therapy at participating site.
robot-assisted tai chi for upper limb rehabilitation in stroke patients

Conditions: Stroke

Summary: this study aims to compare the effectiveness of robot-assisted tai chi training (ratt) versus conventional rehabilitation in improving upper limb motor function post-stroke, and to explore the neuromuscular mechanisms of ratt. participants will be randomly assigned to one of two groups: 1. robot-assisted tai chi training group: participants will receive guided tai chi arm movements with robotic assistance to enhance coordination and strength. 2. conventional rehabilitation group: participants will perform standard exercises (e.g., stretching, repetitive task practice). both groups will receive 60-minute sessions, administered 5 days a week, over 4 weeks. researchers will measure improvements using clinical scales (e.g., fugl-meyer assessment) and monitor safety.


Eligibility criteria:
inclusion criteria: 1. diagnosed with stroke confirmed by neuroimaging (ct/mri). 2. brunnstrom upper extremity stage ⅱ- iii. 3. first-ever stroke with unilateral hemiplegia. 4. aged 40-80 years, regardless of gender. 5. voluntarily participated and provided written informed consent. participants meeting all above criteria were enrolled. exclusion criteria: 1. severe cognitive impairment (montreal cognitive assessment score \<10). 2. poor sitting balance (\ 60 minutes. 3. hypertonia (modified ashworth scale score \>2 in affected limb). 4. significant hemiplegic shoulder pain (visual analogue scale \>3). 5. severe aphasia (boston diagnostic aphasia examination score ≤3). 6. severe visual impairment precluding robot-assisted upper limb training. 7. moderate-to-severe depression (17-item hamilton depression rating scale score \>17). 8. contraindications to mri (e.g., metal implants, claustrophobia). 9. pre-existing neuromuscular disorders, active malignancies, or uncontrolled systemic diseases (cardiac, renal, hepatic). 10. concurrent participation in other clinical trials affecting study outcomes. participants meeting any of the above criteria were excluded.

Keywords: stroke upper limb robot tai chi motor function
comparison of insulin alone to insulin with metformin to treat gestational diabetes mellitus

Conditions: Gestational Diabetes

Summary: this study is a prospective, unmasked randomized clinical trial comparing the use of insulin vs combination insulin and metformin for treatment in women diagnosed with gestational diabetes mellitus (gdm). the investigator's hypothesis is that the combination of metformin and insulin will be superior to insulin alone to achieve tight glucose control during pregnancy.

the objective of this study is to compare the effectiveness of insulin alone vs the combination of insulin and metformin in treating patients with gestational diabetes (gdm). currently, outside of pregnancy, the treatment of type 2 diabetes mellitus (t2dm) with both metformin and insulin is superior to using insulin alone. in pregnancy, insulin alone has traditionally been used, though some advocate the use of metformin alone as primary therapy. there have been no trials published to date specifically comparing combination therapy to insulin alone. our hypothesis is that the combination of metformin and insulin will improve overall control of blood glucose, the improvement of which has been demonstrated to improve maternal and neonatal outcomes. control of blood glucose will be determined by hemoglobin a1c at the time of delivery.

Eligibility criteria:
inclusion criteria: * able to read and write english and/or spanish and give written consent * diagnosis of gdm, defined as an abnormal glucose tolerance test performed after 12 weeks gestation using 1 of the 2 criteria below: * 50 gram 1 hour oral diabetes screening testing yielding a result of \> 200 mg/dl * a 100 gram 3 hour oral glucose tolerance testing yielding \>2 abnormal values (normal values defined as fasting blood glucose \< 95, 1 hour \< 180, 2 hour \< 155 and 3 hour \< 140) * singleton gestation * gestational age between 12 and 34 weeks and 6 days determined by last menstrual period (lmp) confirmed by ultrasound using criteria set forth by the acog (committee on obstetric practice). if lmp is unknown then gestational age must be set by ultrasound prior to 20 weeks gestation. exclusion criteria: * pre-existing dm either by diagnosis preceding pregnancy or hemoglobin a1c \>6.5 collected during the current pregnancy * uncontrolled chronic hypertension, as this may alter maternal and perinatal outcomes measured. * multiple gestations * major fetal anomalies anticipated to require nicu admission * contraindication to metformin (allergy, history of lactic acidosis, pre-existing renal disease (cr \>1.5 mg/dl), active liver disease, current alcohol abuse). * vitamin b12 deficiency, as metformin reduces intestinal absorption of vitamin b12 * medications known to effect glucose metabolism other than insulin and metformin as this may mask any effect between the two treatments. * known inability to tolerate metformin.

Keywords: metformin
a study to determine whether egfr status by fish can predict results in non small cell lung cancer (nsclc) patients treated with cetuximab, carboplatin and paclitaxel

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to determine if egfr status (positive or negative) by fish can predict response to cetuximab therapy in nsclc patients treated with carboplatin and paclitaxel


Eligibility criteria:
inclusion criteria: * subjects who present with stage iv, stage iiib nsclc or recurrent disease following radiation therapy or surgical resection * no prior chemotherapy or anti-egfr targeted therapy * sufficient tumor material for fish testing * measurable disease (recist) * ecog performance status 0 or 1 exclusion criteria: * symptomatic or uncontrolled cns metastases * inadequate hematologic function defined as anc \< 1,500/mm3, platelet count \< 100,000/mm3, or a hemoglobin level \< 9 g/dl * inadequate hepatic function defined as total bilirubin \> 1.25 x uln, ast level \> 1.5 x uln, or alkaline phosphatase \> 5.0 x uln * inadequate renal function defined by a serum creatinine level \> 1.5 x uln
effect of low dose aspirin on birthweight in twins: the gap trial.

Conditions: Small for Gestational Age; Infant, Very Low Birth Weight; Fetal Growth Retardation; Preeclampsia; Premature Birth

Summary: low-dose aspirin started in the first-trimester has been associated with a decrease of preeclampsia, fetal growth restriction and preterm birth in high-risk pregnancies. multiple pregnancies are considered a risk factor for all those adverse outcomes. the main objective of the current trial is to evaluate whether a dose of 80 mg of aspirin is associated with an improvement of birthweight compared to placebo in twin pregnancies.

twin pregnancies represent approximately 3% of births and are associated with increased risks of complications such as preeclampsia, fetal growth restriction and preterm birth. all of these complications are commonly associated impaired placental function and low birth weight. most prophylactic measures tested over the years have failed to prevent these adverse outcomes in twin pregnancies. since administration of low-dose of aspirin can improve placental function and all these adverse outcomes in high-risk pregnancies, mainly in women with prior adverse outcomes, we suggest that similar benefits could be seen in twins. we are expecting that the administration of low-dose of aspirin starting in the first-trimester in twin pregnancies could lead to an improvement of placental function, a reduction or these adverse perinatal outcomes and therefore to an improvement of birthweight.

Eligibility criteria:
inclusion criteria: * gestational age between 8 0/7 and 13 6/7 weeks * twin pregnancy confirmed by ultrasound exclusion criteria: * one or two negative heart beat * previous hypertensive disorder of pregnancy * pre-existing hypertension or diastolic blood pressure \>90 mmhg at randomization * pre-existing nephropathy * pre-existing diabetes (type 1 or 2) * anaphylactic allergy to lactose * known coagulopathy (antithrombin iii deficiency, factor v leiden, antiphospholipid syndrome, the prothrombin mutation, deficiency of protein s or protein c) * use of heparin or other anticoagulants. * contre-indications to aspirin * discordance of crown-rump length greater than 20%. * fetal anomalies (cystic hygroma, nuchal translucency \> 95th percentile, anencephaly, omphalocele, etc.) * previous or current gastric ulcer

Keywords: twin pregnancy pregnancy complications
impulsivity and stimulant administration

Conditions: Cocaine Dependence; Impulsivity

Summary: examine the interaction between stimulants, such as cocaine and methylphenidate, and impulsivity.


Eligibility criteria:
inclusion criteria: 1. age 18 - 50 years, 2. voluntary, written, informed consent, 3. physically healthy by medical history, physical, neurological, ecg, and laboratory examinations, 4. dsm-iv criteria for cocaine abuse (305.60) or cocaine dependence (304.20) 5. recent street cocaine use in excess of amounts to be administered in the current study, 6. intravenous and/or smoked (crack/ freebase) use, 7. positive urine toxicology screen for cocaine, 8. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (β-hcg) test. exclusion criteria: 1. other drug dependence (except nicotine) as determined by urine toxicology or interview 2. \< 1 year of cocaine dependence, 3. a primary major dsm-iv psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine, 4. a history of significant medical (cardiovascular) or neurological illness, ie prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for cardiovascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures parameters re: elevations in vital signs are now explicitly specified under "safety features built into our one-day self-administration paradigm). 5. current use of psychotropic and/or potentially psychoactive prescription medication, 6. seeking treatment for drug abuse/dependence (for experimental cocaine component), 7. physical or laboratory (β-hcg) evidence of pregnancy. 8. current use of any medication (prescription or over-the-counter) determined to cause potential drug interactions by the study physicians.
local thrombolytics before thrombectomy in stemi

Conditions: Coronary Artery Disease

Summary: background prompt reperfusion with percutaneous coronary intervention (pci) in the setting of st-elevation myocardial infarction (stemi) improves clinical outcomes through salvage of myocardial tissue. although the use of thrombus aspiration with pci can result in improved rates of normal epicardial flow and myocardial perfusion, several unmet needs remain. purpose the purpose of this trial will be to evaluate the hypothesis that local delivery of thrombolytics vs. saline infusion prior to thrombus aspiration and pci is safe and effective in patients with stemi.

the study will select patients with st-elevation myocardial infarction (stemi) with angiographic evidence of massive thrombosis in the culprit artery undergoing manual thrombectomy followed by primary percutaneous coronary intervention (pci). patients will be randomized to receive local bolus of 200,000 units urokinase or saline solution

Eligibility criteria:
inclusion criteria: * st-elevation myocardial infarction * angiographic evidence of massive thrombosis in the culprit artery * indication to manual thrombectomy followed by primary percutaneous coronary intervention (pci) * able to understand and willing to sign the informed cf exclusion criteria: * women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before ct

Keywords: thrombectomy